EIDX - BridgeBio announces completion of Eidos Therapeutics deal

BridgeBio Pharma (BBIO) announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics (EIDX).BridgeBio agreed to acquire all of the outstanding common stock of Eidos it did not already own, representing ~36.3% of outstanding shares, in October last year.BridgeBio said that 2021 is poised to be a transformational year for the company with major catalysts in all four drug development programs expected this year or Q1 2022.The company reiterated that it expects to launch two drugs, if approved, this year.

For further details see:

BridgeBio announces completion of Eidos Therapeutics deal